LSO Breakfast Event: Member Marathon
JuneJun 15 2023 07:30am - 10:00am
June 15th, 2023
Marsh - Suite 800, 120 Bremner Blvd, Toronto, ON M5J 0A8
7:30 – 8:00 am – Registration, breakfast and networking
8:00 – 8:10 am – Welcome/Talk from 10KC/Around the room introductions
8:10 – 8:25 am – Envirotainer
8:25 – 8:40 am – Incyte
8:40 – 8:55 am – Livestock Research
8:55 – 9:10 am – Rhythm Pharmaceuticals
9:10 – 10:00 am – Networking
This event is sponsored by Ten Thousand Coffees. Ten Thousand Coffees (10KC) is a diversity-founded all-in-one talent experience platform for inclusive mentoring, connectivity and skills development. 10KC’s all-in-one solutions serve over 200 of the world’s leading companies and social impact organizations including Nike, RBC, EY, Thomson Reuters, PwC, Ascend Leadership and more. Built for the new world of decentralized, remote and hybrid work environments, 10KC’s highly configurable technology helps employers build, scale and measure inclusive talent experience programs that drive engagement, retention and performance. Learn more at 10KC.com
Meet the presenting organizations
Envirotainer is a global market expert in secure cold chain solutions for air transport of biopharmaceuticals. We provide the largest and most advanced fleet of temperature-controlled (-20C to +25C) air cargo containers.
Our new revolutionary CryoSure® platform is designed to maintain deep frozen -70°C temperatures for a duration of up to 8 to 21 days. Our CryoSure® dry ice dewars provide secure handling of cell & therapies, biologics, vaccines, clinical & diagnostics specimens. Through our collaboration and partnerships with qualified experts in the field of temperature-controlled transportation, Envirotainer supports the transport of up to 2M doses of medicine each day to over +3,000 global trade lanes. Whether your organization is engaged in research, pre-clinical, late-stage clinical or commercialized stage of drug development, our solutions provide superior duration, unmatched performance and best value and sustainability for the extreme requirements of the biopharmaceutical industry. Visit us at www.envirotainer.com
Incyte Biosciences Canada is the Canadian affiliate of Incyte Corp (Nasdaq: INCY), a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Creating a robust future for the livestock value chain
LRIC believes that the livestock industry will continue to underpin the prosperity of Ontario. We help to create a bright future through collaborative, creative and practical research and innovation. Our funding comes from all livestock sectors and provincial and federal governments. We provide members with an end to end research system; communication of discoveries in context of the livestock reality; identification of emerging issues; and a focus on a further horizon.
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. Rhythm’s lead asset, IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Event is in progress